CompletedPhase 2

Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients

Italy301 participantsStarted 2020-05-22

Plain-language summary

General objective of the study To assess the efficacy and safety of enoxaparin in hospitalized patients with moderate to severe COVID-19 (Coronavirus Disease 2019) infection. Study Design The study consists of two parts: * a phase II single-arm interventional prospective study including all patients treated with the study drug; * an observational prospective cohort study including all patients screened for receiving the study drug but not included in the phase II study. Patients will be enrolled from "date of study approval" for 1 month. Each patient will be followed-up for a minimum of 90 days after COVID19 diagnosis.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For both interventional study and observational cohort, hospitalized patients are eligible to be included if the following criteria apply: Inclusion criteria: * Age \>=18 y * Microbiologically confirmed COVID-19 infection * Patients with moderate to severe disease according to study definitions (see below) * Informed consent to participate and to use data for interventional study, only to use data for observational cohort Exclusion Criteria: * Participants are excluded from the interventional study if any of the following criteria apply: * Thrombocytopenia (platelet count \< 50.000 mm3) * Coagulopathy: INR (International normalized ratio) \>1.5, aPTT ratio \>1.4 * Impaired renal function (clearance to creatinine less than 15 ml/min) * Known hypersensitivity to heparin * History of heparin induced thrombocytopenia * Presence of an active bleeding or a pathology susceptible of bleeding in presence of anticoagulation (e.g. recent haemorrhagic stroke, peptic ulcer, malignant tumors at hig risk of haemorrhages, recent neurosurgery or ophthalmic surgery, vascular aneurysms, arteriovenous malformations) * Body weight \<45 or \> 150 kg * Concomitant anticoagulant treatment for other indications ( eg atrial fibrillation, venous thromboembolism , prosthetic heart valves). * Dual antiplatelet therapy * Pregnant or breast-feeding women

What they're measuring

Mortality

Timeframe: 30 days and 90 days from the first LMWH subcutaneous injection

Effectivness of enoxaparin on the outcome of COVID 19.

Timeframe: This evaluation will be performed at 30 days and 90 days from the first LMWH subcutaneous injection

ICU admission and length of ICU stay

Timeframe: This evaluation will be performed at 14 days (the last day of treatment adminstration), at 30 days and 90 days from the first LMWH subcutaneous injection

Lenght of hospital stay

Timeframe: This evaluation will be performed at 90 days from admission

Trial details

NCT IDNCT04427098

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-09-29

View on ClinicalTrials.gov More COVID-19 trials